European Medicines Agency has initiated the review of Orion´s dexmedetomidine marketing authorisation application

| Source: Orion Orion 

ORION CORPORATION   STOCK EXCHANGE RELEASE  20 October  2010  AT 4.15  PM
EET




Orion Corporation has submitted a marketing authorisation application for the
intensive care sedative agent dexmedetomidine for the evaluation by the European
Medicines Agency (EMA), the pharmaceutical regulatory authority for the EU
countries. EMA has announced today that  it has validated the centralised
marketing authorisation application and initiated the review. The review time
for a centralised marketing authorisation application typically exceeds one
year.

Orion Corporation

Timo Lappalainen                       Reijo Salonen
President and CEO                    SVP, Research and Development


Contact person:
Reijo Salonen, SVP, Research and Development, phone +358 50 966 3647




Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi



[HUG#1453555]